Kura Oncology reports preclinical data on KO-2806

Kura Oncology reported preclinical data supporting the development of its next-generation farnesyl transferase inhibitor KO-2806 in combination with KRASG12C inhibitors to drive tumor regressions and durable responses in KRASG12C-mutant non-small cell lung cancer, NSCLC. The new findings are being presented in an oral session today at the 5th RAS-Targeted Drug Development Summit in Boston. A copy of the presentation, entitled “Farnesyl Transferase Inhibitors – Evolution from Targeting HRAS to Overcoming Adaptive Resistance to Targeted Therapies.” “Despite advances with KRAS-targeted therapies, a significant unmet need remains for patients with KRASG12C-mutant NSCLC as acquired resistance occurs early and often,” said Francis Burrows, Ph.D., Senior Vice President, Translational Research. “We are highly encouraged by these first preclinical data for KO-2806, which demonstrate the potential for FTIs as a mechanism-based combination agent to enhance antitumor activity of targeted therapies, such as KRASG12C inhibitors.” Kura is on track to dose the first patient in its Phase 1 dose-escalation trial of KO-2806 in the second half of 2023. Concurrent with the monotherapy dose escalation, the Company plans to evaluate KO-2806 in dose-escalation combination cohorts with other targeted therapies in advanced solid tumors, including clear cell renal cell carcinoma and KRASG12C NSCLC.